256 related articles for article (PubMed ID: 29308321)
1. Blocking the CD47-SIRPα axis by delivery of anti-CD47 antibody induces antitumor effects in glioma and glioma stem cells.
Li F; Lv B; Liu Y; Hua T; Han J; Sun C; Xu L; Zhang Z; Feng Z; Cai Y; Zou Y; Ke Y; Jiang X
Oncoimmunology; 2018; 7(2):e1391973. PubMed ID: 29308321
[TBL] [Abstract][Full Text] [Related]
2. Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy.
Schürch CM; Roelli MA; Forster S; Wasmer MH; Brühl F; Maire RS; Di Pancrazio S; Ruepp MD; Giger R; Perren A; Schmitt AM; Krebs P; Charles RP; Dettmer MS
Thyroid; 2019 Jul; 29(7):979-992. PubMed ID: 30938231
[No Abstract] [Full Text] [Related]
3. Cancer immunotherapy targeting the CD47/SIRPα axis.
Weiskopf K
Eur J Cancer; 2017 May; 76():100-109. PubMed ID: 28286286
[TBL] [Abstract][Full Text] [Related]
4. Anti-CD47 Antibody As a Targeted Therapeutic Agent for Human Lung Cancer and Cancer Stem Cells.
Liu L; Zhang L; Yang L; Li H; Li R; Yu J; Yang L; Wei F; Yan C; Sun Q; Zhao H; Yang F; Jin H; Wang J; Wang SE; Ren X
Front Immunol; 2017; 8():404. PubMed ID: 28484448
[TBL] [Abstract][Full Text] [Related]
5. Exosome-SIRPα, a CD47 blockade increases cancer cell phagocytosis.
Koh E; Lee EJ; Nam GH; Hong Y; Cho E; Yang Y; Kim IS
Biomaterials; 2017 Mar; 121():121-129. PubMed ID: 28086180
[TBL] [Abstract][Full Text] [Related]
6. A single-valent long-acting human CD47 antagonist enhances antibody directed phagocytic activities.
Wu F; Qiu Y; Xu Y
Cancer Immunol Immunother; 2020 Dec; 69(12):2561-2569. PubMed ID: 32583154
[TBL] [Abstract][Full Text] [Related]
7. Is CD47 an innate immune checkpoint for tumor evasion?
Liu X; Kwon H; Li Z; Fu YX
J Hematol Oncol; 2017 Jan; 10(1):12. PubMed ID: 28077173
[TBL] [Abstract][Full Text] [Related]
8. Disrupting CD47-SIRPα axis alone or combined with autophagy depletion for the therapy of glioblastoma.
Zhang X; Chen W; Fan J; Wang S; Xian Z; Luan J; Li Y; Wang Y; Nan Y; Luo M; Li S; Tian W; Ju D
Carcinogenesis; 2018 May; 39(5):689-699. PubMed ID: 29538621
[TBL] [Abstract][Full Text] [Related]
9. The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer.
Matlung HL; Szilagyi K; Barclay NA; van den Berg TK
Immunol Rev; 2017 Mar; 276(1):145-164. PubMed ID: 28258703
[TBL] [Abstract][Full Text] [Related]
10. CD20-selective inhibition of CD47-SIRPα "don't eat me" signaling with a bispecific antibody-derivative enhances the anticancer activity of daratumumab, alemtuzumab and obinutuzumab.
van Bommel PE; He Y; Schepel I; Hendriks MAJM; Wiersma VR; van Ginkel RJ; van Meerten T; Ammatuna E; Huls G; Samplonius DF; Helfrich W; Bremer E
Oncoimmunology; 2018; 7(2):e1386361. PubMed ID: 29308308
[TBL] [Abstract][Full Text] [Related]
11. A function-blocking CD47 antibody suppresses stem cell and EGF signaling in triple-negative breast cancer.
Kaur S; Elkahloun AG; Singh SP; Chen QR; Meerzaman DM; Song T; Manu N; Wu W; Mannan P; Garfield SH; Roberts DD
Oncotarget; 2016 Mar; 7(9):10133-52. PubMed ID: 26840086
[TBL] [Abstract][Full Text] [Related]
12. Luteolin promotes macrophage-mediated phagocytosis by inhibiting CD47 pyroglutamation.
Li Z; Gu X; Rao D; Lu M; Wen J; Chen X; Wang H; Cui X; Tang W; Xu S; Wang P; Yu L; Ge X
Transl Oncol; 2021 Aug; 14(8):101129. PubMed ID: 34051623
[TBL] [Abstract][Full Text] [Related]
13. Reduced malignant glioblastoma recurrence post-resection through the anti-CD47 antibody and Temozolomide co-embedded in-situ hydrogel system.
Ye L; Lv W; He W; Li S; Min Z; Gong L; Zhang Q; Teng C; Sun S; Lv L; Guo Y; Xin H
J Control Release; 2023 Jul; 359():224-233. PubMed ID: 37290721
[TBL] [Abstract][Full Text] [Related]
14. Targeting CD47 as a Novel Immunotherapy for Multiple Myeloma.
Sun J; Muz B; Alhallak K; Markovic M; Gurley S; Wang Z; Guenthner N; Wasden K; Fiala M; King J; Kohnen D; Salama NN; Vij R; Azab AK
Cancers (Basel); 2020 Jan; 12(2):. PubMed ID: 32012878
[TBL] [Abstract][Full Text] [Related]
15. Targeting the CD47-SIRPα signaling axis: current studies on B-cell lymphoma immunotherapy.
Zhang J; Jin S; Guo X; Qian W
J Int Med Res; 2018 Nov; 46(11):4418-4426. PubMed ID: 30226089
[TBL] [Abstract][Full Text] [Related]
16. Soluble extracellular domains of human SIRPα and CD47 expressed in Escherichia coli enhances the phagocytosis of leukemia cells by macrophages in vitro.
Lin Y; Yan XQ; Yang F; Yang XW; Jiang X; Zhao XC; Zhu BK; Liu L; Qin HY; Liang YM; Han H
Protein Expr Purif; 2012 Sep; 85(1):109-16. PubMed ID: 22813925
[TBL] [Abstract][Full Text] [Related]
17. TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding.
Petrova PS; Viller NN; Wong M; Pang X; Lin GH; Dodge K; Chai V; Chen H; Lee V; House V; Vigo NT; Jin D; Mutukura T; Charbonneau M; Truong T; Viau S; Johnson LD; Linderoth E; Sievers EL; Maleki Vareki S; Figueredo R; Pampillo M; Koropatnick J; Trudel S; Mbong N; Jin L; Wang JC; Uger RA
Clin Cancer Res; 2017 Feb; 23(4):1068-1079. PubMed ID: 27856600
[No Abstract] [Full Text] [Related]
18. The overall potential of CD47 in cancer immunotherapy: with a focus on gastrointestinal tumors.
Tzatzarakis E; Hissa B; Reissfelder C; Schölch S
Expert Rev Anticancer Ther; 2019 Nov; 19(11):993-999. PubMed ID: 31686549
[No Abstract] [Full Text] [Related]
19. Harnessing Macrophages through the Blockage of CD47: Implications for Acute Myeloid Leukemia.
Melo Garcia L; Barabé F
Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944878
[TBL] [Abstract][Full Text] [Related]
20. CD47 Blockade Inhibits Tumor Progression through Promoting Phagocytosis of Tumor Cells by M2 Polarized Macrophages in Endometrial Cancer.
Gu S; Ni T; Wang J; Liu Y; Fan Q; Wang Y; Huang T; Chu Y; Sun X; Wang Y
J Immunol Res; 2018; 2018():6156757. PubMed ID: 30525058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
